PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Cipaglucosidase Alfa→

Cipaglucosidase Alfa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2359727-71-0
Molecular formula
C4489H6817N1197O1298S32
Molecular weight
99350 g/mol
Drug class
Recombinant human acid alpha-glucosidaseenzyme replacement therapy biologic
Mechanism of action
Replaces deficient lysosomal acid alpha-glucosidase (GAA), enabling lysosomal hydrolysis of glycogen to glucose. The product is used with miglustat, which helps stabilise the enzyme and support cellular uptake.
Indications / reported uses
  • Long-term enzyme replacement therapy in adults with late-onset Pompe disease (GAA deficiency), in combination with miglustat, under the applicable product authorisation

Sources: EMA EPAR — Pombiliti (cipaglucosidase alfa) · US DailyMed — POMBILITI · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Cipaglucosidase Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cipaglucosidase Alfa Permitted Daily Exposure (PDE) report (the Cipaglucosidase Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cipaglucosidase Alfa Occupational Exposure Limit (OEL) report (the Cipaglucosidase Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.